U.S. study of HIFU for prostate cancer resumes in Virginia

October 4, 2007

EDAP TMS S.A. (Vaulx-en-Velin, France) announced the continuation of its U.S. phase II/III clinical trial of treatment using high-intensity focused ultrasound (HIFU) in men with prostate cancer. An additional two patients have been treated at Virginia Urology Center, Richmond, where Anthony Sliwinski, MD, and David Miller, MD, are leading the study.

EDAP TMS S.A. (Vaulx-en-Velin, France) announced the continuation of its U.S. phase II/III clinical trial of treatment using high-intensity focused ultrasound (HIFU) in men with prostate cancer. An additional two patients have been treated at Virginia Urology Center, Richmond, where Anthony Sliwinski, MD, and David Miller, MD, are leading the study.

"The EDAP Ablatherm-HIFU equipment is very easy to use. The ultrasound technology and safety features of the equipment make my part effortless," Dr. Sliwinski said. "Thus far, we have treated four men using this technology. Our first two patients had a very positive experience and an immediate reduction in their PSA results. Both men have been enthusiastic spokesmen for this procedure.

"Our most recent treatments lasted shortly over 2 hours, and immediate results seem excellent. This procedure appears to be a wonderful alternative to the many current treatment options for prostate cancer."

The study is currently enrolling men over age 50 years diagnosed with clinical stage T1a, T1b, T1c, or T2a localized prostate cancer.